Randomized phase III study of 1 month versus 1 year of adjuvant high-dose interferon alfa-2b in patients with resected high-risk melanoma
D Pectasides, U Dafni, D Bafaloukos… - Journal of Clinical …, 2009 - ascopubs.org
Purpose A high-dose interferon alfa (IFN-α) regimen as reported in E1684 was unique for
the incorporation of an induction phase of maximally tolerated dosages of intravenous (IV) …
the incorporation of an induction phase of maximally tolerated dosages of intravenous (IV) …
[引用][C] Randomized Phase III Study of 1 Month Versus 1 Year of Adjuvant High-Dose Interferon Alfa-2b in Patients With Resected High-Risk Melanoma
D PECTASIDES, U DAFNI… - Journal of clinical …, 2009 - pascal-francis.inist.fr
Randomized Phase III Study of 1 Month Versus 1 Year of Adjuvant High-Dose Interferon Alfa-2b
in Patients With Resected High-Risk Melanoma CNRS Inist Pascal-Francis CNRS Pascal …
in Patients With Resected High-Risk Melanoma CNRS Inist Pascal-Francis CNRS Pascal …
Randomized phase III study of 1 month versus 1 year of adjuvant high-dose interferon alfa-2b in patients with resected high-risk melanoma
D Pectasides, U Dafni, D Bafaloukos… - Journal of clinical …, 2009 - pubmed.ncbi.nlm.nih.gov
Purpose A high-dose interferon alfa (IFN-alpha) regimen as reported in E1684 was unique
for the incorporation of an induction phase of maximally tolerated dosages of intravenous …
for the incorporation of an induction phase of maximally tolerated dosages of intravenous …
Randomized phase III study of 1 month versus 1 year of adjuvant high-dose interferon alfa-2b in patients with resected high-risk melanoma.
D Pectasides, U Dafni, D Bafaloukos, D Skarlos… - hecog.gr
PURPOSE: A high-dose interferon alfa (IFN-alpha) regimen as reported in E1684 was
unique for the incorporation of an induction phase of maximally tolerated dosages of …
unique for the incorporation of an induction phase of maximally tolerated dosages of …
Randomized phase III study of 1 month versus 1 year of adjuvant high-dose interferon alfa-2b in patients with resected high-risk melanoma.
D Pectasides, U Dafni, D Bafaloukos… - Journal of Clinical …, 2009 - europepmc.org
Purpose A high-dose interferon alfa (IFN-alpha) regimen as reported in E1684 was unique
for the incorporation of an induction phase of maximally tolerated dosages of intravenous …
for the incorporation of an induction phase of maximally tolerated dosages of intravenous …
[PDF][PDF] Randomized Phase III Study of 1 Month Versus 1 Year of Adjuvant High-Dose Interferon Alfa-2b in Patients With Resected High-Risk Melanoma
D Pectasides, U Dafni, D Bafaloukos, D Skarlos… - Clinical …, 2007 - academia.edu
Purpose A high-dose interferon alfa (IFN-) regimen as reported in E1684 was unique for the
incorporation of an induction phase of maximally tolerated dosages of intravenous (IV) …
incorporation of an induction phase of maximally tolerated dosages of intravenous (IV) …
[PDF][PDF] Randomized Phase III Study of 1 Month Versus 1 Year of Adjuvant High-Dose Interferon Alfa-2b in Patients With Resected High-Risk Melanoma
D Pectasides, U Dafni, D Bafaloukos, D Skarlos… - Clinical …, 2007 - academia.edu
Purpose A high-dose interferon alfa (IFN-) regimen as reported in E1684 was unique for the
incorporation of an induction phase of maximally tolerated dosages of intravenous (IV) …
incorporation of an induction phase of maximally tolerated dosages of intravenous (IV) …